Douglas Jermasek - Jul 11, 2023 Form 4 Insider Report for Unicycive Therapeutics, Inc. (UNCY)

Role
EVP of Corporate Strategy
Signature
/s/ Douglas Jermasek
Stock symbol
UNCY
Transactions as of
Jul 11, 2023
Transactions value $
-$50,000
Form type
4
Date filed
7/13/2023, 07:33 PM
Previous filing
Mar 9, 2023
Next filing
Aug 30, 2023

Transactions Table

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Ownership Footnotes
transaction UNCY Common Stock Options Exercise +105K +148.6% 175K Jul 11, 2023 Direct F1

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Underlying Class Amount Exercise Price Ownership Footnotes
transaction UNCY Series A-1 Convertible Preferred Stock Options Exercise -$50K -50 -100% $1,000.00* 0 Jul 11, 2023 Common Stock $0.49 Direct F2
transaction UNCY Warrant (right to buy Options Exercise +79.3K 79.3K Jul 11, 2023 Series A-3 Convertible Preferred Stock 79.3K $0.54 Direct F1, F3
transaction UNCY Warrant (right to buy) Options Exercise +72K 72K Jul 11, 2023 Series A-4 Convertible Preferred Stock 72K $0.59 Direct F1, F4
transaction UNCY Warrant (right to buy) Options Exercise +115K 115K Jul 11, 2023 Series A-5 Convertible Preferred Stock 115K $0.74 Direct F1, F5
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 The reported securities were included within the units issued to the reporting person upon conversion of the Series A-1 Convertible Preferred Stock. The Series A-1 Convertible Preferred Stock converted into units at an exercise price of $0.49 per share.
F2 On July 11, 2023, the shares of Series A-1 Convertible Preferred Stock automatically converted into units consisting of (1) 104,612 shares of common stock, (2) a Tranche A Warrant to purchase 79,252 shares of Series A-3 Convertible Preferred Stock, (3) a Tranche B Warrant to purchase 72,047 shares of Series A-4 Convertible Preferred Stock and (4) a Tranche C Warrant to purchase 115,275 shares of Series A-5 Convertible Preferred Stock. The shares of Series A-1 Convertible Preferred Stock had no expiration date prior to conversion.
F3 The Tranche A Warrants issued to the reporting person as part of the units issued upon conversion of the Series A-1 Convertible Preferred Stock expire twenty-one (21) days following the Issuer's announcement of receipt of FDA approval for Renazorb.
F4 The Tranche B Warrants issued to the reporting person as part of the units issued upon conversion of the Series A-1 Convertible Preferred Stock expire twenty-one (21) days following the Company's announcement of receipt of Transitional Drug Add-On Payment Adjustment approval for Renazorb.
F5 The Tranche C Warrants issued to the reporting person as part of the units issued upon conversion of the Series A-1 Convertible Preferred Stock expire twenty-one (21) days following the Company's public disclosure of financial results for four (4) quarters of commercial sales of Renazorb following receipt of Transitional Drug Add-On Payment Adjustment approval for Renazorb, commencing with the first quarter in which the Company receives revenue from Centers for Medicare and Medicaid Services for Renazorb under the Transitional Drug Add-On Payment Adjustment.